Spasticity Treatment Beyond Botulinum Toxins

Sheng Li; Paul Winston; Manuel F Mas

doi:10.1016/j.pmr.2023.06.009

Spasticity Treatment Beyond Botulinum Toxins

Phys Med Rehabil Clin N Am. 2024 May;35(2):399-418. doi: 10.1016/j.pmr.2023.06.009. Epub 2023 Aug 12.

Authors

Sheng Li¹, Paul Winston², Manuel F Mas³

Affiliations

¹ Department of Physical Medicine and Rehabilitation, McGovern Medical School, University of Texas Health Science Center - Houston, Houston, TX, USA; TIRR Memorial Herman. Electronic address: sheng.li@uth.tmc.edu.
² Division of Physical Medicine and Rehabilitation, University of British Columbia, Victoria, British Columbia, Canada; Canadian Advances in Neuro-Orthopedics for Spasticity Consortium, Victoria, British Columbia, Canada.
³ Department of Physical Medicine and Rehabilitation, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.

PMID: 38514226
DOI: 10.1016/j.pmr.2023.06.009

Abstract

Botulinum toxin (BonT) is the mainstream treatment option for post-stroke spasticity. BoNT therapy may not be adequate in those with severe spasticity. There are a number of emerging treatment options for spasticity management. In this paper, we focus on innovative and revived treatment options that can be alternative or complementary to BoNT therapy, including phenol neurolysis, cryoneurolysis, and extracorporeal shock wave therapy.

Keywords: Cryoneurolysis; Extracorporeal shock wave therapy (ESWT); Phenol neurolysis; Spasticity; Stroke.

Publication types

Review

MeSH terms

Botulinum Toxins, Type A* / therapeutic use
Humans
Muscle Spasticity / drug therapy
Muscle Spasticity / etiology
Neuromuscular Agents* / therapeutic use
Stroke* / complications
Stroke* / drug therapy
Treatment Outcome

Substances

Botulinum Toxins, Type A
Neuromuscular Agents